Allergan agrees to acquire AqueSys for $300 million
Life Sciences
Business Deals
(MarketWatch) – Allergan PLC said late Thursday it agreed to acquire privately-held AqueSys Inc. for $300 million cash. AqueSys makes medical devices that are placed in the eye to reduce pressure associated with glaucoma. Allergan said that it will also pay milestone payments for regulatory approval and commercialization of AqueSys’s XEN45 device, which is expected to get U.S. approval in late 2016 or early 2017. Allergan plans to close the acquisition in the fourth quarter.
Decades ago, the founder-led biotech was rare and considered the tougher path to follow. Now there is a trend of founder-led biotechs that have risen in prominence in recent years, going from startup to well known with lightning speed. Scientists-turned C-suite occupants know their technology inside out. They’ve got credibility both at the bench working with their research teams and in the boardrooms selling their future products.
Pfizer’s revenue could reach $101.3 billion in 2022, with major contributions coming from the company’s BioNTech-partnered COVID vaccine and an antiviral therapeutic that has shown stellar clinical data, SVB Leerink analyst Geoffrey Porges projected in a Monday note to clients.
In a survey commissioned by GlaxoSmithKline’s consumer health division of 2,000 working people in the U.S., almost 70% admitted to clocking in while sick, often because they couldn’t afford to lose a day’s pay. Black and Latina women were 10% more likely than white women to shun taking sick time for fear of fallout from their boss, according to the company’s 2021 Temperature Check Report.
